AT1-receptor blockade and the kidney: importance of non-ACE pathways in health and disease

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S59-S63

  Hollenberg, N K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme; Angiotensin II; Candesartan; Captopril; Diabetes; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALKIREN; ENZYME INHIBITOR; EPROSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RENIN; RENIN INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; DRUG URINE LEVEL; ENZYME INHIBITION; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; METABOLIC ACTIVATION; NONHUMAN; OBESITY; PATHOGENESIS; PROTEINURIA; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; RISK FACTOR; SALT INTAKE; SODIUM RESTRICTION; TISSUE INJURY; VOLUNTEER;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; REFERENCE VALUES; RENIN-ANGIOTENSIN SYSTEM;

EID: 0036672353     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001441     Document Type: Article

References (25)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456 - 1462.
2. Lewis EJ Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
3. Brenner BM Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl Med 2001; 345: 861-869.
4. Parving H-H The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl Med 2001;345: 870-878.
5. Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs 2001; 10: 417- 426.
6. Urata H Angiotensin Il-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.
7. Okunishi H Marked species-difference in the vascular angiotensin Il-forming pathways: humans versus rodents. Jap J Pharmacol 1993; 62: 207-210.
8. Powell JS The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition.Cardiovasc Pharmacol 1990; 16 (Suppl 4): S42-S49.
9. Powell JS Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-188.
10. The MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86: 100 -110.
11. Hollenberg NK. The renin-angiotensin-aldosterone system, blockade and diabetic nephropathy. JRAAS2001; 2 (Suppl 1): S185-S187.
12. Cordero P Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. Hypertension 1991; 17: 510-516.
13. Hollenberg NK, Fisher NK. Renal circulation and blockade of the renin-angiotensin system. Is angioten- sin-converting enzyme inhibition the last word? Hypertension 1995; 26: 602-609.
14. Price DA, De’Oliveira JM, Fisher NDL, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension1997; 39: 240-246.
15. Price DA The paradox of the low-renin state in diabetic nephropathy.Am Soc Nephrol 1999; 10: 2382-2391.
16. Hollenberg NK Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. JRÂAS 2001; 2: 14-18.
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
18. Marre M Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. Clin Invest 1997; 99: 1585-1595.
19. Hadjadj S Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study, Am Soc Nephrol 2001; 12: 541-549.
20. Lansang MC Renal vascular responses to capto- pril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001; 59: 1432-1438.
21. Ikoma M Cause of variable therapeutic efficacy of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991; 40: 195-202.
22. Palla R Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function. Int J Clin Pharmacol Res 1994; 14: 35-43.
23. Gansevoort RT Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease./Hypertens 1994; 12 (Suppl): S37-S42.
24. Weinberg MS, Weinberg AJ, Cord R, Zappe DH. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS 2001; 2 (Suppl 1): S196-S198.
25. Osei SY Hyperglycemia and angiotensin- mediated control of the renal circulation in healthy humans. Hypertension 1999; 3: 559-564.